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T his paper summarizes the responses of a groupof panelists to the topic of methodology issues
in the pharmacoeconomics of lipid-lowering ther-
apies, presented earlier by Susan Andrade, Tom
Delea, Bruce Kinosian, and Joel Hay. Moderated
by Sanford Schwartz, the panel included Alistair
McGuire, Talat Ashraf, and Nicolaas Otten. Reac-
tions and comments of meeting participants follow.
Moderator: We will start by asking the panel to
share their reactions, thoughts, or comments in
the area of methodology issues in lipid pharrnaco-
economic studies.
Alistair McGuire: I'll begin with a general trend
from the last two papers [Kinosian, Hay, this issue]
by asking, "How does one know which model to
believe?" Even if models are available on the Inter-
net, how do we know which one to take?
Bruce Kinosian: I think the models should be
subjected to the same kinds of tests, assuming the
data is available, that usually are required in other
predicted models. One has to see how well cali-
brated they are and how well they discriminate. It
is now possible to do this because outcome data
are available. However, this data may not be
readily available to everyone. Unless you happen
to work for the owners of the right outcome data,
you are left with a trial that's 20 years old. An ear-
lier suggestion by the Moderator to make the out-
come results from studies, such as the West of
Scotland Coronary Prevention Study (WOSCOPS)
[1], the Scandinavian Simvastatin Survival Study
(4S) [2], and the Cholesterol and Recurrent Events
(CARE) study [3], available to investigators would
be a real advance for the field. The results from
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these trials could be used to test models and vali-
date them.
Alistair McGuire: An added requirement should
be that along with the data, the regression analy-
ses should be reported.
Bruce Kinosian: Not only the regression test and
input parameters, but also the functional form used,
because very different answers can be obtained de-
pending upon the functional form employed.
Talat Ashraf Journals do not appear to be equipped
to handle the details of regression analysis. When
one sends regression equations to the journal, 35
pages are submitted and 25 pages come back, ask-
ing that they be put into an appendix. It is also
asked that the details be sent only to those inter-
ested. So that's one of the basic problems: we do
send regression equations, but they come back.
Bruce Kinosian: I would say that showing the re-
sults of how well calibrated your model is would be
more useful than sending the regression equations.
Steve Grover has set a standard dictating that one
should show that a model is calibrated. One diffi-
culty with his calibrations, however, is that they are
calibrated at the mean. So, individual patient pre-
dictions are needed to do the validations.
Joel Hay: To address the question of which model
one should chose, you have to consider your prefer-
ences. The kind of modeling that Tom Delea pre-
sented (frontier analysis) [Delea, this issue], that
Bruce Kinosian presented (based on clinical trials)
[Kinosian, this issue], and the type of modeling
that I presented, are very different. One uses sur-
rogate markers and one uses actual outcomes data
from clinical trials. The preferences of the deci-
sion-maker and what kind of uncertainty they are
willing to accept will dictate what kind of models
to use. If knowing the relationship between a sur-
rogate marker and an actual end-point is impor-
tant, then perhaps frontier analysis should not be
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used; if you accept surrogate markers, then that
would imply something else.
Moderator: My guess is that if you take the re-
sults of 45 (2], CARE [3], and WOSCOPS [1] and
you substituted each one of those results into the
other model of the same disease, you would end
up with three different results for each trial. The
problem then becomes, "How is a decision-maker
going to assess the relative cost-effectiveness of
one drug versus another or one intervention ver-
sus another?" It isn't because the models have dif-
ferent assumptions; it is because they have differ-
ent functional forms. The models have different
inputs that vary more than just the inputs of the
trial results themselves, and that makes them hard
to use. Perhaps the answer is, as Joel Hay sug-
gested, to require people to put their models in the
public domain. People wouldn't be able to own
their models anymore, but that is the price of pub-
lishing. With simple models, it was relatively easy
to read an article in a journal, redraw the decision
tree, and, using the given parameter estimates, you
could substitute numbers and use the model. But
the models we arc dealing with here are at a differ-
ent level of complexity.
Nicolaas Otten: What does the decision-maker
want in all this? We have several different models
with different results, different assumptions, and it
gets very complex to sort through. However, no
matter which models we have been looking at
here, we know that somewhere in the spectrum of
these lipid-lowering therapies, treatments are cost-
effective. And that was the desired result. What
we don't know is where to start and where to
stop, and that's where more data collection and
more validation of the models come in. We then
have to add the real-world situations. From Susan
Andrade's study [Andrade, this issue], reviewing
utilization patterns shows that how people are or
are not taking their prescribed medication varies
substantially. In Canada, besides the study Susan
mentioned from Saskatchewan, there is also one
from Quebec that has very different results. In
Saskatchewan, looking at all lipid-lowering agents
at the end of 1 year, only 25% were taking their
lipid-lowering agents. The average length of time
on therapy was 3.7 months. So, economic evalua-
tions out to 5 years and then models to 15 years
don't really matter if people are not taking their
medication. It is fine to model, but we have to
start some up-front work, not only with patient
compliance but also with the prescribing habits of
physicians. Utilization patterns and prescribing
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patterns of physicians bear little resemblance to
the results in the literature. I think that modeling
tells us what the potential is, but there is much
work to do in terms of actually seeing the kind of
benefits that we are predicting with these models.
Talat Ashraf: We have done some relationship
studies and found they are not linear, so I don't
accept the idea of models based on percentage
changes. The fundamental flaw with the percent-
age change model is that it is assumed that a 1%
reduction in LDL has the same quality for all
treatments, but in real life it doesn't have the same
quality. Niacin treatment is different from treat-
ment with statins, so you cannot really do percent-
age change models. On the other hand, models
based on clinical trials (Hay, this issue] have more
flexibility in this regard.
There are a lot of questions being asked from a
managed care perspective these days that are not
being answered. Why? Those in managed care
want definitive answers to how individual drugs
apply to their own plans, and realistically, we do
not always respond to these questions with abso-
lute answers. It is asked that models be custom-
ized to mimic what happens with a particular drug
in their plan. We can perhaps do this with models
based on coefficients, customizing the model to a
particular managed care situation.
A second issue is that those in managed care
want evidence in their setting for the outcomes at-
tributed to a drug. If 10 fewer myocardial infarc-
tions (MIs) are expected by 5 years, some imply,
"Let's wait 5 years and see if, in fact, 10 fewer
MIs did happen in my plan." How can we address
this?
The third story involves the response of man-
aged care to evidence from the literature support-
ing the use of statins to avert MIs. If one says that,
as soon as a patient has an MI, statin should be
prescribed, managed care asks, "Why?" All trials
prescribed pravastatin 3 months after an MI, so
managed care feels that prescribing pravastatin
immediately after having an MI is unnecessary.
How can we answer that?
To give another example, we went to a physi-
cian group and asked why pravastatin or simvas-
tatin or lovastatin were not being prescribed to
patients who had experienced an MI. The commu-
nity physician answered that while the patient was
in the hospital, the hospital physicians did not
think it was necessary to prescribe statin. If all the
tests that had been done in the hospital indicated
no statin treatment, then the community physician
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offered no treatment. The real-life issue is that if a
patient who was prescribed a statin as primary
prevention for 2 years has an MI on statin and
goes to the hospital, should you keep on prescrib-
ing a statin when the patient comes out of the hos-
pital? These are the kind of issues community phy-
sicians are asking. These are the type of questions
managed care gatekeepers are asking. While I
don't think there is a dear answer, I also feel that
we may not have presented things clearly to the
physicians who would be prescribing these drugs
on a daily basis. We are looking at numbers of
cost per year of life saved, and that's good for de-
cision analysis, but it won't get the drugs pre-
scribed to patients.
The final issue I want to mention has to do with
compliance. The value of 60% discontinuation af-
ter the first year comes from somewhere, but man-
aged care won't accept that those prescribed statin
will only stay on the drug for 5.8 months; they see
the patient as staying in their plan for 2 years and
consider 100% compliance to be unnecessary.
Moderator: Susan [Andrade], do you have any re-
sponses to the compliance issues that were raised?
Did you look at physician prescribing at all?
Alistair McGuire: Could I add in something here
on compliance? Did you look at the characteristics
of noncompliance at all? Because the figures are so
different from one study to another, did they have
similar characteristics?
Susan Andrade: In our study, factors associated
with discontinuations were looked at. It was found
that patient gender and previous discontinuation of
therapy were the biggest predictors, but this was not
found in other studies such as the Australian study
or the Saskatchewan study [Andrade, this issue].
Moderator: In the paper delivered earlier, it was
mentioned that in Australia the compliance rates
were much lower because the people didn't believe
that lipid-lowering therapy was going to do any-
thing for them. I was wondering about the role of
public education in trying to improve compliance
as opposed to doctors talking to patients.
Susan Andrade: I think both are necessary. First,
if we cannot convince the physicians that a treat-
ment is important, we are not going to get the pa-
tients to believe it is important. The patients' main
support system should be the clinicians who work
together with them to treat their condition. Evi-
dently, the system is not presently optimal.
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Joel Hay: To comment on the issue of compli-
ance, it is interesting that if a straight naive eco-
nomic analysis of compliance is done with the as-
sumption that the effectiveness of the lipid therapy
is linearly related to the amount of compliance,
one can actually show that it's more cost-effective
if patients are not compliant along certain levels.
And it may turn out to be true, that taking therapy
every other day, or only taking enough therapy to
get to 20% LDL reduction using some type of
noncompliance, may actually be a much more
cost-effective strategy. Only more research will
answer this. These types of models can be used to
assist in making decisions today about real-world
therapy, with the fundamental advantage of mod-
els-done properly and laid out clearly-being
that one can question them, challenge them, or
change them as needed. To be useful, models must
be presented in a logical and consistent way with
assumptions and parameters of analysis laid out in
a completely transparent fashion.
Nicolaas Otten: How much of an impact did
non-healthcare costs like those due to employee
productivity over the 5 years have in the model
you presented [Hay, this issue]? Also, how was.
this calculated for various ages, such as older age
groups versus younger people, or for men or
women not in the workforce?
Joel Hay: The employee productivity analysis
that was done took data from the National Health
Interview Survey for the United States. In the main
part of the study, analysis was only done for males
aged 45-64 for comparison with the West of Scot-
land [1] treatment group. The female lifetime pro-
jections that were done included cost per year of
life saved, but not any employee productivity. In
this cohort (males aged 45-64) one doesn't have to
worry about the retirement factor. This group has
extremely high labor force participation, about
75%. We multiplied workforce participation by av-
erage employee compensation based on Bureau of
Labor statistics data. We used the National Health
Interview Survey to look at both the increased
number of sick days reported by patients with is-
chemic heart disease over and above sick days re-
ported by people that did not have ischemic heart
disease, as well as the dropout from workforce
due to condition.
Moderator: If older people, say 65, 70, or 75
years of age, were included in the analysis, what
would you have done?
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Joel Hay: To adjust for employee productivity in
a retirement age population where there is less em-
ployee productivity than in a nonretirernent age
population, I think the willingness to pay argu-
ment should be used. As a society, we are willing
to pay to keep people alive beyond the point at
which they stop being productive members of the
workforce. This population has utility and value;
economics is not about just productivity, it's also
about utility and benefits.
Alistair McGuire: One issue that has been raised
in these discussions is whether or not we should
do economics alongside trials, which partly under-
lies this idea of modeling and partly underlies the
efficacy versus effectiveness idea. There is a whole
school of thought that says that trials are not rep-
resentative of the heterogeneity of a population
that you are aiming to treat. Clinical trials tend to
screen out patients with cornorbidities. Perhaps
the argument then becomes a trade-off as to
whether or not modeling should be done solely on
effectiveness with costs added in with the assump-
tions at the outset versus using the trial results at
all. This argument saddens me because there is a
lot of empirical evidence that lipid-lowering thera-
pies work, and people aren't changing their prac-
tices. Where are the incentives within the system to
get people to, first of all, change their clinical prac-
tice given the evidence, and, secondly, change the
budget allocations given that it's going to be costly
to have effective treatment introduced?
Talat Ashraf: I personally think that every physi-
cian believes that decreases in LDL or reduction of
LDLIHDL ratios do have clinical benefits. Treat-
ing a patient with high cholesterol to reduce heart
disease is a reasonable argument, but why is it not
practiced? It is a community-based logistical issue
that takes into consideration patient behavior and
responsiveness; so, while every physician knows
that this is a very good thing to do, it is not always
practiced.
Bruce Kinosian: It seems that revascularizarion
procedures are used much more than lipid-lower-
ing drugs. Apart from the economic incentive to
do procedures, if one goes to managed care plans
where your interventionists are salaried and they
don't get more money for doing procedures, you
still have a lot more procedures done. To use an
analogy, there seems to be much more attention to
the plumbing than there is to the respective modi-
fication of the clogged pipes. If one looks at the re-
vascularization studies, lipid-lowering drugs are a
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lot cheaper and a lot more effective at preventing
MIs than revascularization. Yet, I'm sure that if
you surveyed physicians, that is not the answer
you would get. Perhaps part of it has to do with
education.
Nicolaas Otten: Changing one's behavior, whether
a patient's or a physician's, is a very difficult thing.
It's not that people don't believe that the changes
are good. But altering people's habits is difficult. It
has been shown that a 30% change in terms of
hard outcomes would result in a change in behav-
ior. There has to be feedback, an interactive situa-
tion, to show patients and physicians the impact
of what they are doing.
Moderator: This is a question for Bruce Kino-
sian. You showed a slide indicating that in 4S al-
most twice the benefit was obtained from getting
somebody in the treatment group down to a cer-
tain LDL level compared to if that person was at
the same level in the placebo group. Is this analo-
gous to what Jim Shepherd went through this
morning on the West of Scotland study, which
showed that in groups with overlapping levels,
people in the treatment group get greater benefit?
Bruce Kinosian: No, it's not analogous. In the
overlap group model, the level of LDL cholesterol
determines one's destiny, and there is a difference
in moving from a higher level to a lower level. Per-
haps this has to do with what Dan Rader talked
about earlier at this conference in terms of plaque
stabilization: reaching a lower LDL level in the
treatment group rather than if one was always at
that level.
Now, in the analysis of the 4S data, one can es-
timate the risk equation from the placebo group,
substitute the lipid levels of the treatment group,
and then look at the actual treatment results from
a coefficient on treatment assignment. In this case,
one sees about 90% more CHD events averted in
the treatment group than would be predicted
purely from the observed lipid changes.
Moderator: To what can that be attributed?
Bruce Kinosian: It probably has to do with a few
different things, including plaque stabilization and
perhaps some factors related to statins in general.
This "greater than maximum" benefit can be seen
with two different kinds of statins and also with
cholestyrarnine. So, people with plaques at a cer-
tain level of risk get more benefits from treatment
than what you'd predict for people who always
were at that lower level.
Methodology Issues
Mark Hlatky: Earlier today, Dr. Schwartz men-
tioned the ways that preventive measures have
been adopted in the United States. Sometimes
these were adopted by individuals, and their life-
style changed. Sometimes health plans or insurers
paid for treatment, and other times a societal deci-
sion was made that something was good, which
encouraged other people to implement it. One ex-
ample is immunization for children. I firmly be-
lieve in them, but the typical managed care plan
that provides these immunizations doesn't gain
from them because these children, particularly in
Medicaid programs, have a turnover of over 50%
per year. So the original managed care provider is
not there when the benefits occur from immuniza-
tion. Secondly, when there is a long time horizon
associated with benefits of a therapy, it will have
to be proven that this is beneficial to society using
various other intermediate measures. It also won't
be easy to sell to a managed care plan because, if
they were the only providers of the treatment, ev-
erybody at high risk for the disorder would join
that plan and they would be overwhelmed. They
won't gain any benefit from it in the short run, so
perhaps a certain societal rigor will have to be im-
posed. When it becomes required, then managed
care plans will look into the most cost-effective way
of providing this necessary service or these neces-
sary prescriptions. Lastly, it would be very interest-
ing to see how many people would use a medica-
tion if they had to pay for it entirely by themselves.
Even if it is their lives that would be saved or en-
hanced, I don't think you'd sell very much of that
medication. To summarize, it is a question of cost
incidence, not just cost and effectiveness.
Talat Ashraf: Perhaps immunization is not a
good example. Getting back to lipid-lowering
therapies, it is unlikely that any managed care or-
ganization would tell their physicians not to treat
a patient with hyperlipidemia. Managed care may
not have a policy on it, but every managed care
organization I know has an antihyperlipidemic
agent on the formulary. So the issue really isn't
that managed care is not convinced of the thera-
pies: they do have statins on the formulary.
Rather, it is the physicians and the patients who
are not convinced. It's a benign disease. If one has
hyperlipidemia, nothing happens immediately, daily
activities go on until one may have a myocardial
infarction. Even then, patients who have myocar-
dial infarctions don't take this therapy post-MI.
So, with immunization, the cost is for about two
shots per child in the plan, whereas with lipid-
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lowering therapy, the cost of medication is for
about 20 years. So it's a different kind of scenario
in terms of cost: one is a few million dollars in the
plans, of which a part may be paid by the state,
versus a multimillion-dollar cost. These two cases
are really not comparable.
Moderator: We get impatient when we know
there is a treatment of value we can offer and even
more impatient in how long it takes to change be-
havior. We can perhaps learn from other chronic
diseases like diabetes and hypertension about
changing behavior effectively, or ineffectively.
Speaker 1: It is difficult to be both advocate and
analyst in many situations; we worry about per-
suading people that our model is accurate and
valid. Perhaps those of us who see ourselves prima-
rily as analysts, economists, epidemiologists, and
such would be better served if we worried less
about providing people with the answer ourselves,
meaning a simple point estimate of cost-effective-
ness and whether it is above or below some appro-
priate threshold. Rather, providing good informa-
tion to persons in positions that can make use of
the information should be a priority. Tom Delea's
presentation [Delea, this issue] of efficiency fron-
tiers was very important in this respect. In fact, he
may have undersold that approach by limiting it to
surrogate markers. Bruce Kinosian [Kinosian, this
issue] applied the same frontier approach to a life-
years-saved measure of effectiveness. The point is,
instead of trying to summarize all this information
in a simple ratio that is very limited, the audience is
given more complete information with assumptions
clearly explained. Joel Hay's suggestion [Hay, this
issue] that there is nothing wrong with models
provided that they are clearly and transparently
presented to the audience is key.
Moderator: The importance of the model is not
necessarily a point estimate, but understanding what
is driving the model and under what conditions
the model might hold. When a model is presented
and a result of cost per year of life saved is given,
it can be put into one of three categories. Is it
clearly cost-effective? Is it clearly not cost-effec-
tive? Or is this going to be a judgment call? There
are so many variations that go into how a model is
created. My feeling is you can't take published
models from peer-reviewed journals and compare
one number to another number because the mod-
els are so different.
Speaker 2: The lipid field is an area where we re-
ally do have a lot of outcomes data; there are
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about 150,000 patient years of rigorous follow-up
in randomized controlled clinical trials. It is ironic
that treatment to goal in diabetes and hypertension,
where there is less rigorous data on specific prod-
ucts and specific therapeutic interventions, is ac-
cepted; however, for lipid-lowering agents, treat-
ment patterns are much less aggressive.
Moderator: In hypertension, the issue really is
about prevention, and physicians in the United
States are not very oriented toward prevention. The
medical profession is being coerced in that direc-
tion, but it is going to take a long time to achieve.
Bruce Kinosian: The major difference between
diabetes goals and lipid goals has to do with the
more immediate consequences of not treating dia-
betes to goal. However, very few people think
they suffer any sequelae from hyperlipidemia, so
clearly, time horizons vary between the two.
Moderator: To close, in this session we have
clearly identified some of the real-world problems
and limitations of treating patients with lipid-lower-
ing therapies. However, the management of hyper-
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lipidernia, as well as the attitudes and the knowl-
edge of how to manage it, have been advanced not
only by the clinical trials but also by the economic
analysis of lipid-lowering agents that have been
presented.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
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